NEW YORK (GenomeWeb News) — The US federal anti-trust waiting period has passed on Roche’s hostile takeover bid for Ventana Medical Systems, Roche said today.
  
The expiration of the Hart-Scott-Rodino waiting period satisfies one condition of Roche’s offer, under which it would buy all of Ventana’s outstanding shares for $75 in cash per share, or $3 billion.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.